In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was suitable for patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) who are intolerant to ibrutinib (Imbruvica). This study concluded that acalabrutinib was effective and well tolerated in these patients. Some...
Read More
In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia-lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...
Read More
In a nutshell This study aimed to investigate if combined CD19 and CD22 chimeric antigen receptor (CAR) T-cell therapies could be used to treat patients with relapsed acute lymphoblastic leukemia (ALL) after transplant. This study concluded that this combination improved long-term survival for these patients. Some...
Read More
In a nutshell This article aimed to outline updates to the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of acute myeloid leukemia (AML). Some background The NCCN Guidelines for AML provide recommendations for the diagnosis and treatment of AML. The recommendations are based on clinical...
Read More
In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2 x 4 doses) with or without blinatumomab (Blincyto) in patients with...
Read More
In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting. This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...
Read More
In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...
Read More
In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...
Read More
In a nutshell This study aimed to investigate the outcomes for pediatric patients with acute myeloid leukemia (AML) treated with the MASPORE 2006 protocol. This study concluded that this treatment protocol provided improved outcomes for these patients when compared to earlier treatment protocols. Some background From 1997 to 2006, children...
Read More
In a nutshell This study aimed to compare dasatinib (Sprycel) and nilotinib (Tasigna) as second-line treatments for patients with chronic-phase (CP) chronic myeloid leukemia (CML) in a real-life setting. This study concluded that both dasatinib and nilotinib are equally effective and well...
Read More
In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...
Read More
In a nutshell This review aims to analyze the trials that led to acalabrutinib (Calquence) gaining regulatory approval in the European Union for the treatment of chronic lymphocytic leukemia (CLL). Some background Acalabrutrinib is a targeted therapy mainly used for the treatment of non-Hodgkin lymphoma. It...
Read More
